TGTX FY 2023 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$234M+8290.0% YoY

Gross Profit

$220M94.0% margin

Operating Income

$21M8.8% margin

Net Income

$13M5.4% margin

EPS (Diluted)

$0.09

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$31M

Stock-Based Comp.

$38M

Balance Sheet

Total Assets

$330M

Total Liabilities

$169M

Stockholders' Equity

$161M

Cash & Equivalents

$93M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$234M	$3M	+8290.0%
Gross Profit	$220M	$3M	+8611.5%
Operating Income	$21M	-$218M	+109.5%
Net Income	$13M	-$224M	+105.7%